RedHill Biopharma Ltd. (RDHL:NASDAQ) closed at $0.480 on October 16, 2026, down 3.81% on the day. The stock trades 77.6% below its 52-week high of $2.14 and 10.4% above its 52-week low of $0.435. Over the past year, it lost 68.0%. RedHill Biopharma Ltd. is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -9.99% | -19.04% | -31.41% | -39.30% | -67.99% |
In 252 trading sessions since October 16, 2025, RDHL closed higher on 89 days (35%). Its best day was August 31, 2026 (+36.16%) and its worst was June 9, 2026 (-21.57%). The stock moved 10% or more in a single session 16 times. It opened at least 5% above the previous day's high 3 times.
RedHill Biopharma Ltd., an Israeli biopharmaceutical company, focuses on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. The company's pipeline of therapeutic candidates include RHB-105 intended for the eradication of Helicobacter pylori infection that is under Phase III study; RHB-104 for the treatment of Crohn's disease, which is under Phase III study; BEKINDA for the prevention of chemotherapy and radiotherapy induced nausea and vomiting, and gastroenteritis and gastritis that is under phase III study; and RHB-106 intended for the preparation and cleansing of the gastrointestinal tract. Its pipeline of therapeutic candidates also comprise MESUPRON, a urokinase-type plasminogen activator inhibitor targeting gastrointestinal and other solid tumor cancers that has completed Phase II-stage; RP101, a Hsp27 inhibitor for the treatment of pancreatic and other gastrointestinal cancers; RIZAPORT, an oral thin film formulation of rizatriptan for acute migraines; and RHB-101 for the treatment of hypertension, heart failure, and left ventricular dysfunction. The com...
Find more stocks like RDHL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.